Insulin resistance and hyperinsulinemia contribute to polycystic ovary syndrome (PCOS), and the study aimed to compare metformin alone against metformin combined with Myoinositol and d-chiro-inositol in treatment outcomes for PCOS patients.
Conducted over 6 months, the randomized controlled trial included overweight and obese women aged 18-35 with PCOS, divided into two treatment groups to assess various health parameters.
Results showed that both treatments improved menstrual cycle regularity, but the myoinositol group had significantly better outcomes in quality of life, while pregnancy rates were similar; other hormonal and metabolic improvements weren't statistically significant.